3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Multiple Myeloma
235
Precursor Cell Lymphoblastic Leukemia-Lymphoma
69
Recurrence
36
Burkitt Lymphoma
34
Leukemia
32
Lymphoma
30
Neoplasms, Plasma Cell
22
Lymphoma, Non-Hodgkin
19
Immunoglobulin Light-chain Amyloidosis
18
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, Mantle-Cell
16
Neoplasms
15
Nausea
15
Lymphoma, Large B-Cell, Diffuse
15
Vomiting
14
Hodgkin Disease
13
Breast Neoplasms
12
Waldenstrom Macroglobulinemia
11
Leukemia, Biphenotypic, Acute
11
Lymphoma, Follicular
10
Lymphoma, B-Cell, Marginal Zone
10
Amyloidosis
10
Lung Neoplasms
9
Smoldering Multiple Myeloma
8
Prostatic Neoplasms
8
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Hematologic Neoplasms
7
Blast Crisis
7
Lymphoma, T-Cell, Cutaneous
6
Interventions
pembrolizumab
188
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
belzutifan
5
Dexamethasone
5
durvalumab
4
Surgical Procedures, Operative
4
Radiotherapy
4
Nivolumab
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Calcium Dobesilate
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts